Form 4: Emergent BioSolutions GC Tax-Related Share Sale

Emergent BioSolutions' SVP, General Counsel, and Corporate Secretary, Jessica Perl, reported a future transaction on February 9, 2026, involving the disposal of 918 common shares to cover tax obligations from restricted stock unit vesting.

Summary

• Jessica Perl, SVP, General Counsel, and Corporate Secretary of Emergent BioSolutions Inc. (EBS), reported a planned transaction under a Rule 10b5-1 plan.
• On February 9, 2026, 918 shares of common stock are scheduled to be disposed of.
• This disposal is specifically to cover tax liabilities associated with the vesting and settlement of restricted stock units.
• The shares were valued at $11.03 each for the purpose of this tax withholding.
• Following this transaction, Ms. Perl will beneficially own 67,469 shares of Emergent BioSolutions common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine, non-discretionary insider transaction related to tax obligations from RSU vesting, which typically has a neutral impact on market sentiment.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction, beyond the scheduled insider transaction.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those related to tax withholding upon RSU vesting, are common across all industries for executives receiving equity compensation. This specific transaction by Emergent BioSolutions' General Counsel is a routine event and does not indicate any unique industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, non-discretionary transaction for tax purposes, not a discretionary sale reflecting a change in investment sentiment.

Key Dates

Keywords

Emergent BioSolutions, EBS, Insider Transaction, Form 4, Restricted Stock Units, Tax Withholding, Jessica Perl, Corporate Secretary, General Counsel